Skip Page Header

Home > Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs.

European Monitoring Centre for Drugs and Drug Addiction. (2002) Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs. Luxembourg: Office for Official Publications of the European Communities.

[img]
Preview
PDF (EMCDDA Risk assessment PMMA) - Published Version
1MB

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It has been associated, in combination with PMA, with three deaths in the EU. PMMA is devoid of any therapeutic value.

Further to the conclusions of the EMCDDA risk assessment, on 28 February 2002, the Council of the European Union adopted a unanimous decision defining the new synthetic drug PMMA (para-methoxymethylamphetamine) as a substance to be placed under control measures and criminal penalties in the EU Member States

Table of contents
• Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs
• Council decision
• Europol-EMCDDA progress report on PMMA and PMA
• Review of the pharmacotoxicological data on PMMA
• Sociological and criminological evidence on the risks of PMMA
• Public health risks of PMMA: epidemiological evidence


Item Type
Report
Publication Type
International, Report
Drug Type
New psychoactive substance
Date
2002
Call No
REF, EMCDDA
Pages
122 p.
Publisher
Office for Official Publications of the European Communities
Corporate Creators
European Monitoring Centre for Drugs and Drug Addiction
Place of Publication
Luxembourg
ISBN
92-9168-137-7
Edition
EMCDDA Risk Assessment Series No. 5
EndNote
Accession Number
HRB 4489 (Available)
Related (external) link

Repository Staff Only: item control page